Last reviewed · How we verify
Clinical Trial Phase I / II Multicenter, Randomized, Crossover, Double-blind Evaluation of the Safety and Feasibility of Systemic Therapy With Mesenchymal Cells Derived From Autologous Bone Marrow in Patients With Multiple Sclerosis
This is a phase I / II for the evaluation of the safety and feasibility of intravenous infusion of mesenchymal cells from autologous bone marrow in patients with Multiple Sclerosis. Intravenous administration of autologous mesenchymal cells of bone marrow is feasible and safe and can be effective in treating patients suffering from multiple sclerosis.
Details
| Lead sponsor | Andalusian Initiative for Advanced Therapies - Fundación Pública Andaluza Progreso y Salud |
|---|---|
| Phase | Phase 1/Phase 2 |
| Status | COMPLETED |
| Enrolment | 26 |
| Start date | 2013-01 |
| Completion | 2020-06-30 |
Conditions
- Multiple Sclerosis
Interventions
- Bone marrow mesenchymal stem cells autologous
- Placebo comparator
Primary outcomes
- Absence of unexpected serious adverse reactions as a measure of safety and reduction in number and volumes of the lesions on magnetic resonance image — 12 months
Countries
Spain